Vagus nerve stimulation

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Vagus nerve stimulation
Vagus nerve stimulation.jpg
Electrical stimulation of vagus nerve.
Other namesVagal nerve stimulation

Vagus nerve stimulation (VNS) is a medical treatment that involves delivering electrical impulses to the vagus nerve. It is used as an add-on treatment for certain types of intractable epilepsy and treatment-resistant depression.

Medical use[edit]

VNS devices are used to treat drug-resistant epilepsy and treatment-resistant major depressive disorder (TR-MDD).[1][2][3]

In the United States, VNS is approved as adjunctive therapy for those 4 years of age or older with refractory focal onset seizures. In the European Union, VNS is approved as an adjunctive therapy for patients with either generalized or focal onset seizures without any age restrictions.[4] It is recommended that VNS is only pursued following an adequate trial of at least 2 appropriately chosen anti-seizure medications and that the patient is ineligible for epilepsy surgery.[5] This is because epilepsy surgery is associated with a higher probability of resulting in seizure freedom.[6] Patients who have poor adherence or tolerance of anti-seizure medications may be good candidates for VNS.[7] Patients with comorbid depression have been found to have mood improvements with VNS therapy.[8]

VNS may provide benefit for particular epilepsy syndromes and seizure types such as Lennox-Gastaut syndrome, tuberous sclerosis complex related epilepsy, refractory absence seizures and atonic seizures.[9][10][11][12] There are also reports of VNS being successfully utilized in patients with refractory and super-refractory status epilepticus.[13]  

Efficacy[edit]

Epilepsy[edit]

A meta-analysis of 74 clinical studies with 3321 patients found that VNS produced an average 51% reduction in seizures after 1 year of therapy.[14] Approximately 50% of patients had an equal to or greater than 50% reduction in seizures at the time of last follow-up.[14] Long term studies have shown that response to VNS increases over time. For instance, a study that followed 74 patients for 10-17 years found a seizure frequency reduction of 50-90% in 38.4%, 51.4%, 63.6% and 77.8% of patients at 1-, 2-, 10- and 17-years following implantation, respectively.[15] Approximately, 8% have total resolution of seizures.[16] VNS has also been shown to reduce rates of sudden unexpected death in epilepsy (SUDEP) and to improve quality of life metrics.[17][18] A number of predictors of a favorable clinical response have been identified including epilepsy onset > 12 years of age, generalized epilepsy type, non-lesional epilepsy, posttraumatic epilepsy and those who have less than a 10 year history of seizures.[14][16][19]

Depression[edit]

As of 2017, the efficacy of VNS for TR-MDD is unclear.[1][3] A 2022 narrative review concluded that "The use of VNS is an approved, effective and well-tolerated long-term therapy for chronic and treatment-resistant depression. Further sham-controlled studies over a longer observational period are desirable".[20][21]

Mechanism of action[edit]

The vagus nerve is the tenth cranial nerve and arises from a series of rootlets in the medulla; it carries both afferent (80%) and efferent (20%) fibers. It has the longest and widest distribution of all the cranial nerves and functions as a bidirectional link between the brain and peripheral organs. Afferents from the vagus nerve project to the nucleus tractus solitarius which subsequently communicates with other regions of the brain including the dorsal raphe nucleus, locus coeruleus, amygdala and other areas.[22]

There are multiple potential mechanisms which may account for the efficacy of VNS in treating epilepsy and other conditions including:

1.   There is evidence that VNS results in cortical desynchronization in epilepsy patients who had a favorable clinical response relative to those who did not.[23][24][25] This makes sense given that seizures consist of abnormal hypersynchronous activity in the brain.

2.   Multiple lines of evidence suggest that inflammation plays a significant role in epilepsy as well as associated neurobehavioral comorbidities such as depression, autism spectrum disorder and cognitive impairment.[26] There is evidence that VNS has an anti-inflammatory effect through both peripheral and central mechanisms.[22]

3.   VNS can change the activity of several neurotransmitter systems involving serotonin, norepinephrine and GABA.[27][28] These neurotransmitters are involved in both epilepsy and other neuropsychiatric conditions such as depression and anxiety.

4.   VNS may alter the functional connectivity in several brain regions and enhance synaptic plasticity to reduce excitatory activity involved in seizures.[29][30] It has also been shown to change the functional connectivity of the default mode network in depressed patients.[31]

Adverse events[edit]

There are two categories of adverse events associated with VNS: (1) those related to the surgical procedure and (2) those related to stimulation. A large 25-year retrospective study of 247 patients found a surgical complication rate of 8.6%.[32] The common adverse events included infection in 2.6%, hematoma at the surgical site in 1.9% and vocal cord palsy in 1.4%.[32] The most common stimulation related side effect at 1 year following implantation are hoarseness in 28% and paraesthesias in the throat-chin region in 12%.[33] At the third year the rate of stimulation related adverse effects decreased substantially with shortness of breath being the most common and occurring in 3.2%.[33] In general, VNS is well tolerated and side effects diminish over time. Also, side effects can be controlled by changing the stimulation parameters.

There is evidence that VNS can induce sleep apnea in as many as 28% of adult patients.[34]

Devices and procedures[edit]

The device consists of a generator the size of a matchbox that is implanted under the skin below the person’s collarbone. Lead wires from the generator are tunnelled up to the patient’s neck and wrapped around the left vagus nerve at the carotid sheath, where it delivers electrical impulses to the nerve.[1]

Implantation of the VNS device is usually done as an out-patient procedure. The procedure goes as follows: an incision is made in the upper left chest and the generator is implanted into a little "pouch" on the left chest under the collarbone. A second incision is made in the neck, so that the surgeon can access the vagus nerve. The surgeon then wraps the leads around the left branch of the vagus nerve, and connects the electrodes to the generator. Once successfully implanted, the generator sends electric impulses to the vagus nerve at regular intervals. The left vagus nerve is stimulated rather than the right because the right plays a role in cardiac function such that stimulating it could have negative cardiac effects.[3][35] The "dose" administered by the device then needs to be set, which is done via a magnetic wand; the parameters adjusted include current, frequency, pulse width, and duty cycle.[3]

"Wearable" devices are being tested and developed that involve transcutaneous stimulation and do not require surgery. Electrical impulses are targeted at the aurical (ear), at points where branches of the vagus nerve have cutaneous representation; such devices had been tested in clinical trials for treatment resistant major depressive disorder as of 2017.[3][36]

History[edit]

Early History[edit]

James L. Corning (1855-1923) was an American neurologist who developed the first device for stimulating the vagus nerve towards the end of the 19th century.[37] At that time a widely held theory was that excessive blood flow caused seizures.[37] In the 1880s Corning designed a pronged instrument called the “carotid fork” to compress the carotid artery for the acute treatment of seizures. In addition, he developed the “carotid truss” for prolonged compression of the carotid arteries as a long-term preventative treatment for epilepsy. Then he developed the “electrocompressor” which allowed for the compression of the bilateral carotid arteries as well as electrical stimulation of both the vagus and cervical sympathetic nerves. The idea was to reduce cardiac output and to stimulate cervical sympathetic nerves to constrict cerebral blood vessels. Corning reported dramatic benefits however it was not accepted by his colleagues and ultimately was forgotten.[37]

In the 1930s Biley and Bremer demonstrated the direct influence of VNS on the central nervous system.[38] This was in contrary to Corning who had intended to use it to reduce cerebral blood flow. In the 1940s and 1950s vagal nerve stimulation was shown to affect EEG activity.[39] Finally, nearly 100 years since Corning, Zabara proposed that VNS could be used to treat epilepsy.[40] He then demonstrated its efficacy in animal experiments.[41] The first human was implanted with a VNS for the treatment of epilepsy in 1988.[42]

Later History[edit]

In 1997, the US Food and Drug Administration's neurological devices panel met to consider approval of an implanted vagus nerve stimulator (VNS) for epilepsy, requested by Cyberonics (which was subsequently acquired by LivaNova).[1]

The FDA approved an implanted VNS for TR-MDD in 2005.[3]

In April 2017, the FDA cleared marketing of a handheld noninvasive vagus nerve stimulator, called "gammaCore" and made by ElectroCore LLC, for episodic cluster headaches, under the de novo pathway.[43][44] In January 2018, the FDA cleared a new use of that device, for the treatment of migraine pain in adults under a 510(k) based on the de novo clearance.[45][46]

In 2020, electroCore's non-invasive VNS was granted an Emergency Use Authorization for treating COVID-19 patients, given Research has shown this pulse train causes airways in the lungs to open its anti-inflammatory effect.[47]

Research[edit]

Because the vagus nerve is associated with many different functions and brain regions, clinical research has been done to determine its usefulness in treating other illnesses, including various anxiety disorders,[48] obesity,[49][50] alcohol addiction,[51] chronic heart failure,[52] prevention of arrhythmias that can cause sudden cardiac death,[53] autoimmune disorders,[54][55] irritable bowel syndrome,[56][57][58] Alzheimer's disease,[59][60] Parkinson's disease,[61] hypertension,[62][63] and several chronic pain conditions.[64] A recent study showed that chronic VNS showed strong antidepressant and anxiolytic effects, and improved memory performance in an Alzheimer's Disease animal model.[65]

tVNS has also been shown to enhance memory in healthy adults.[66][67]

VNS has also been studied in small trials of people with neurodevelopmental disorders, generally who also have had epilepsy, including Landau-Kleffner syndrome, Rett syndrome, and autism spectrum disorders.[68] VNS is being studied as of 2018 as a treatment for migraines and fibromyalgia.[69][70]

Transcutaneous[edit]

As of 2015, VNS devices were being developed that were not implanted, but rather transmitted signals through the skin, known as transcutaneous vagus nerve stimulation (tVNS). Electrical impulses are targeted at the auricle of the ear at points where branches of the vagus nerve are close to the surface.[3][36] It is non-invasive and based on the rationale that there is vagus nerve distribution on the surface of the ear. tVNS is being studied for stroke and the treatment of depression.[71][72]

See also[edit]

References[edit]

  1. ^ a b c d Edwards CA, Kouzani A, Lee KH, Ross EK (September 2017). "Neurostimulation Devices for the Treatment of Neurologic Disorders". Mayo Clinic Proceedings. 92 (9): 1427–1444. doi:10.1016/j.mayocp.2017.05.005. PMID 28870357. open access
  2. ^ Panebianco, Mariangela; Rigby, Alexandra; Marson, Anthony G. (2022-07-14). "Vagus nerve stimulation for focal seizures". The Cochrane Database of Systematic Reviews. 2022 (7): CD002896. doi:10.1002/14651858.CD002896.pub3. ISSN 1469-493X. PMC 9281624. PMID 35833911.
  3. ^ a b c d e f g Carreno FR, Frazer A (July 2017). "Vagal Nerve Stimulation for Treatment-Resistant Depression". Neurotherapeutics. 14 (3): 716–727. doi:10.1007/s13311-017-0537-8. PMC 5509631. PMID 28585221.
  4. ^ Wheless, James W.; Gienapp, Andrew J.; Ryvlin, Phillippe (2018-11-01). "Vagus nerve stimulation (VNS) therapy update". Epilepsy & Behavior. 88: 2–10. doi:10.1016/j.yebeh.2018.06.032. ISSN 1525-5050. PMID 30017839. S2CID 51679627.
  5. ^ Morris, G. L.; Gloss, D.; Buchhalter, J.; Mack, K. J.; Nickels, K.; Harden, C. (2013-08-28). "Evidence-based guideline update: Vagus nerve stimulation for the treatment of epilepsy: Report of the Guideline Development Subcommittee of the American Academy of Neurology". Neurology. 81 (16): 1453–1459. doi:10.1212/wnl.0b013e3182a393d1. ISSN 0028-3878. PMC 3806910. PMID 23986299.
  6. ^ Fisher, R. S.; Handforth, A. (1999-09-11). "Reassessment: vagus nerve stimulation for epilepsy: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 53 (4): 666–669. doi:10.1212/wnl.53.4.666. ISSN 0028-3878. PMID 10489023. S2CID 20845641.
  7. ^ Helmers, Sandra L.; Duh, Mei Sheng; Guérin, Annie; Sarda, Sujata P.; Samuelson, Thomas M.; Bunker, Mark T.; Olin, Bryan D.; Jackson, Stanley D.; Faught, Edward (2011-10-01). "Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy". Epilepsy & Behavior. 22 (2): 370–375. doi:10.1016/j.yebeh.2011.07.020. ISSN 1525-5069. PMID 21872534. S2CID 7869407.
  8. ^ Fan, Jing-Jing; Shan, Wei; Wu, Jian-Ping; Wang, Qun (2019-08-19). "Research progress of vagus nerve stimulation in the treatment of epilepsy". CNS Neuroscience & Therapeutics. 25 (11): 1222–1228. doi:10.1111/cns.13209. ISSN 1755-5949. PMC 6834923. PMID 31429206.
  9. ^ Grioni, Daniele; Landi, Andrea (2019-01-01). "Does Vagal Nerve Stimulation Treat Drug-Resistant Epilepsy in Patients with Tuberous Sclerosis Complex?". World Neurosurgery. 121: 251–253. doi:10.1016/j.wneu.2018.10.077. ISSN 1878-8750. PMID 30347295. S2CID 53034756.
  10. ^ Braakman, Hilde M.; Creemers, Joke; Hilkman, Danny M.; Klinkenberg, Sylvia; Koudijs, Suzanne M.; Debeij-van Hall, Mariette; Cornips, Erwin M. (2018). "Improved seizure control and regaining cognitive milestones after vagus nerve stimulation revision surgery in Lennox–Gastaut syndrome". Epilepsy & Behavior Case Reports. 10: 111–113. doi:10.1016/j.ebcr.2018.08.002. ISSN 2213-3232. PMC 6197149. PMID 30364578.
  11. ^ Arya, Ravindra; Greiner, Hansel M.; Lewis, Amanda; Mangano, Francesco T.; Gonsalves, Cornelia; Holland, Katherine D.; Glauser, Tracy A. (2013-05-01). "Vagus nerve stimulation for medically refractory absence epilepsy". Seizure. 22 (4): 267–270. doi:10.1016/j.seizure.2013.01.008. ISSN 1059-1311. PMID 23391567. S2CID 14917920.
  12. ^ Rolston, John D.; Englot, Dario J.; Wang, Doris D.; Garcia, Paul A.; Chang, Edward F. (2015-10-01). "Corpus callosotomy versus vagus nerve stimulation for atonic seizures and drop attacks: A systematic review". Epilepsy & Behavior. 51: 13–17. doi:10.1016/j.yebeh.2015.06.001. ISSN 1525-5050. PMC 5261864. PMID 26247311.
  13. ^ Dibué-Adjei, Maxine; Brigo, Francesco; Yamamoto, Takamichi; Vonck, Kristl; Trinka, Eugen (2019-09-01). "Vagus nerve stimulation in refractory and super-refractory status epilepticus – A systematic review". Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation. 12 (5): 1101–1110. doi:10.1016/j.brs.2019.05.011. ISSN 1935-861X. PMID 31126871. S2CID 153310356.
  14. ^ a b c Englot, Dario J.; Chang, Edward F.; Auguste, Kurtis I. (2011-12-01). "Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response". Journal of Neurosurgery. 115 (6): 1248–1255. doi:10.3171/2011.7.JNS11977. ISSN 1933-0693. PMID 21838505.
  15. ^ Chrastina, Jan; Novák, Zdeněk; Zeman, Tomáš; Kočvarová, Jitka; Pail, Martin; Doležalová, Irena; Jarkovský, Jiří; Brázdil, Milan (2018-07-01). "Single-center long-term results of vagus nerve stimulation for epilepsy: A 10–17 year follow-up study". Seizure. 59: 41–47. doi:10.1016/j.seizure.2018.04.022. ISSN 1059-1311. PMID 29738985. S2CID 13700901.
  16. ^ a b Englot, Dario J.; Rolston, John D.; Wright, Clinton W.; Hassnain, Kevin H.; Chang, Edward F. (2016-09-01). "Rates and Predictors of Seizure Freedom With Vagus Nerve Stimulation for Intractable Epilepsy". Neurosurgery. 79 (3): 345–353. doi:10.1227/NEU.0000000000001165. ISSN 1524-4040. PMC 4884552. PMID 26645965.
  17. ^ Englot, Dario J.; Hassnain, Kevin H.; Rolston, John D.; Harward, Stephen C.; Sinha, Saurabh R.; Haglund, Michael M. (2017-01-01). "Quality-of-life metrics with vagus nerve stimulation for epilepsy from provider survey data". Epilepsy & Behavior. 66: 4–9. doi:10.1016/j.yebeh.2016.10.005. ISSN 1525-5050. PMC 5258831. PMID 27974275.
  18. ^ Ryvlin, Philippe; So, Elson L.; Gordon, Charles M.; Hesdorffer, Dale C.; Sperling, Michael R.; Devinsky, Orrin; Bunker, Mark T.; Olin, Bryan; Friedman, Daniel (2018-01-16). "Long-term surveillance of SUDEP in drug-resistant epilepsy patients treated with VNS therapy". Epilepsia. 59 (3): 562–572. doi:10.1111/epi.14002. ISSN 0013-9580. PMID 29336017. S2CID 3782079.
  19. ^ Englot, Dario J.; Rolston, John D.; Wang, Doris D.; Hassnain, Kevin H.; Gordon, Charles M.; Chang, Edward F. (2012-09-14). "Efficacy of vagus nerve stimulation in posttraumatic versus nontraumatic epilepsy". Journal of Neurosurgery. 117 (5): 970–977. doi:10.3171/2012.8.jns122. ISSN 0022-3085. PMID 22978542.
  20. ^ Reif-Leonhard, C.; Reif, A.; Baune, B. T.; Kavakbasi, E. (5 April 2022). "Vagusnervstimulation bei schwer zu behandelnden Depressionen". Der Nervenarzt (in German). Springer Science and Business Media LLC. 93 (9): 921–930. doi:10.1007/s00115-022-01282-6. ISSN 0028-2804. PMC 9452433. PMID 35380222.
  21. ^ Kron, Thomas (5 May 2022). "Vagus Nerve Stimulation: A Little-Known Option for Depression". Medscape.
  22. ^ a b Wang, Yue; Zhan, Gaofeng; Cai, Ziwen; Jiao, Bo; Zhao, Yilin; Li, Shiyong; Luo, Ailin (2021-08-01). "Vagus nerve stimulation in brain diseases: Therapeutic applications and biological mechanisms". Neuroscience & Biobehavioral Reviews. 127: 37–53. doi:10.1016/j.neubiorev.2021.04.018. ISSN 0149-7634. PMID 33894241. S2CID 233328858.
  23. ^ Fraschini, Matteo; Puligheddu, Monica; Demuru, Matteo; Polizzi, Lorenzo; Maleci, Alberto; Tamburini, Giorgio; Congia, Socrate; Bortolato, Marco; Marrosu, Francesco (2013-03-01). "VNS induced desynchronization in gamma bands correlates with positive clinical outcome in temporal lobe pharmacoresistant epilepsy". Neuroscience Letters. 536: 14–18. doi:10.1016/j.neulet.2012.12.044. ISSN 0304-3940. PMID 23333601. S2CID 25790383.
  24. ^ Sangare, Aude; Marchi, Angela; Pruvost-Robieux, Estelle; Soufflet, Christine; Crepon, Benoit; Ramdani, Céline; Chassoux, Francine; Turak, Baris; Landre, Elisabeth; Gavaret, Martine (2020-12-01). "The Effectiveness of Vagus Nerve Stimulation in Drug-Resistant Epilepsy Correlates with Vagus Nerve Stimulation-Induced Electroencephalography Desynchronization". Brain Connectivity. 10 (10): 566–577. doi:10.1089/brain.2020.0798. ISSN 2158-0014. PMC 7757623. PMID 33073582.
  25. ^ Joseph, Navya Mary; Steffan, Paul; Becker, Danielle; Wernovsky, Magda; Datta, Proleta; Ernst, Lia (2022-05-27). "Effects of VNS stimulation on electrocorticography in patients with dual neuro- stimulation devices". Journal of Neurology, Neurosurgery & Psychiatry. 93 (6): A3.3–A4. doi:10.1136/jnnp-2022-abn.9. ISSN 0022-3050.
  26. ^ Paudel, Yam Nath; Shaikh, Mohd. Farooq; Shah, Sadia; Kumari, Yatinesh; Othman, Iekhsan (2018-10-15). "Role of inflammation in epilepsy and neurobehavioral comorbidities: Implication for therapy". European Journal of Pharmacology. 837: 145–155. doi:10.1016/j.ejphar.2018.08.020. ISSN 0014-2999. PMID 30125565. S2CID 52048111.
  27. ^ Manta, Stella; El Mansari, Mostafa; Debonnel, Guy; Blier, Pierre (2012-04-17). "Electrophysiological and neurochemical effects of long-term vagus nerve stimulation on the rat monoaminergic systems". International Journal of Neuropsychopharmacology. 16 (2): 459–470. doi:10.1017/s1461145712000387. ISSN 1469-5111. PMID 22717062.
  28. ^ Furmaga, Havan; Shah, Aparna; Frazer, Alan (2011-11-15). "Serotonergic and noradrenergic pathways are required for the anxiolytic-like and antidepressant-like behavioral effects of repeated vagal nerve stimulation in rats". Biological Psychiatry. 70 (10): 937–945. doi:10.1016/j.biopsych.2011.07.020. ISSN 1873-2402. PMID 21907323. S2CID 206101850.
  29. ^ Alexander, Georgia M.; Huang, Yang Zhong; Soderblom, Erik J.; He, Xiao-Ping; Moseley, M. Arthur; McNamara, James O. (2016-12-14). "Vagal nerve stimulation modifies neuronal activity and the proteome of excitatory synapses of amygdala/piriform cortex". Journal of Neurochemistry. 140 (4): 629–644. doi:10.1111/jnc.13931. ISSN 0022-3042. PMC 6537100. PMID 27973753.
  30. ^ Zhu, Jin; Xu, Cuiping; Zhang, Xi; Qiao, Liang; Wang, Xueyuan; Zhang, Xiaohua; Yan, Xiaoming; Ni, Duanyu; Yu, Tao; Zhang, Guojun; Li, Yongjie (2020-08-17). "A resting-state functional MRI study on the effect of vagal nerve stimulation on spontaneous regional brain activity in drug-resistant epilepsy patients". Behavioural Brain Research. 392: 112709. doi:10.1016/j.bbr.2020.112709. ISSN 0166-4328. PMID 32479850. S2CID 219123829.
  31. ^ Fang, Jiliang; Rong, Peijing; Hong, Yang; Fan, Yangyang; Liu, Jun; Wang, Honghong; Zhang, Guolei; Chen, Xiaoyan; Shi, Shan; Wang, Liping; Liu, Rupeng; Hwang, Jiwon; Li, Zhengjie; Tao, Jing; Wang, Yang (2016-02-15). "Transcutaneous Vagus Nerve Stimulation Modulates Default Mode Network in Major Depressive Disorder". Biological Psychiatry. 79 (4): 266–273. doi:10.1016/j.biopsych.2015.03.025. ISSN 0006-3223. PMC 4838995. PMID 25963932.
  32. ^ a b Révész, David; Rydenhag, Bertil; Ben-Menachem, Elinor (2016-07-01). "Complications and safety of vagus nerve stimulation: 25 years of experience at a single center". Journal of Neurosurgery: Pediatrics. 18 (1): 97–104. doi:10.3171/2016.1.peds15534. ISSN 1933-0707. PMID 27015521.
  33. ^ a b Coughlin, Maryanne K. (2001-10-01). "Long-Term Treatment with Vagus Nerve Stimulation in Patients with Refractory Epilepsy". AORN Journal. 74 (4): 554. doi:10.1016/s0001-2092(06)61692-x. ISSN 0001-2092.
  34. ^ Salvadé, Aude; Ryvlin, Philippe; Rossetti, Andrea O. (2018-02-01). "Impact of vagus nerve stimulation on sleep-related breathing disorders in adults with epilepsy". Epilepsy & Behavior. 79: 126–129. doi:10.1016/j.yebeh.2017.10.040. ISSN 1525-5050. PMID 29287215. S2CID 46769980.
  35. ^ Giordano F, Zicca A, Barba C, Guerrini R, Genitori L (April 2017). "Vagus nerve stimulation: Surgical technique of implantation and revision and related morbidity". Epilepsia. 58 (Suppl 1): 85–90. doi:10.1111/epi.13678. PMID 28386925.
  36. ^ a b Van Leusden JW, Sellaro R, Colzato LS (2015). "Transcutaneous Vagal Nerve Stimulation (tVNS): a new neuromodulation tool in healthy humans?". Frontiers in Psychology. 6 (102): 102. doi:10.3389/fpsyg.2015.00102. PMC 4322601. PMID 25713547.
  37. ^ a b c Lanska, D. J. (2002-02-12). "J.L. Corning and vagal nerve stimulation for seizures in the 1880s". Neurology. 58 (3): 452–459. doi:10.1212/wnl.58.3.452. ISSN 0028-3878. PMID 11839848.
  38. ^ Bailey, Percival; Bremer, Frédéric (1938-09-01). "A Sensory Cortical Representation of the Vagus Nerve: With a Note on the Effects of Low Blood Pressure on the Cortical Electrogram". Journal of Neurophysiology. 1 (5): 405–412. doi:10.1152/jn.1938.1.5.405. ISSN 0022-3077.
  39. ^ George, M. S.; Sackeim, H. A.; Rush, A. J.; Marangell, L. B.; Nahas, Z.; Husain, M. M.; Lisanby, S.; Burt, T.; Goldman, J.; Ballenger, J. C. (2000-02-15). "Vagus nerve stimulation: a new tool for brain research and therapy". Biological Psychiatry. 47 (4): 287–295. doi:10.1016/s0006-3223(99)00308-x. ISSN 0006-3223. PMID 10686263. S2CID 14489190.
  40. ^ Zabara, J. (1985-09-01). "Peripheral control of hypersynchronous discharge in epilepsy". Electroencephalography and Clinical Neurophysiology. 61 (3): S162. doi:10.1016/0013-4694(85)90626-1. ISSN 0013-4694.
  41. ^ Zabara, Jacob (1992-11-01). "Inhibition of Experimental Seizures in Canines by Repetitive Vagal Stimulation". Epilepsia. 33 (6): 1005–1012. doi:10.1111/j.1528-1157.1992.tb01751.x. ISSN 0013-9580. PMID 1464256. S2CID 19290172.
  42. ^ Penry, J. Kiffin; Dean, J. Christine (1990-06-01). "Prevention of Intractable Partial Seizures by Intermittent Vagal Stimulation in Humans: Preliminary Results". Epilepsia. 31 (s2): S40–S43. doi:10.1111/j.1528-1157.1990.tb05848.x. ISSN 0013-9580. PMID 2121469. S2CID 32134763.
  43. ^ Brauser D (April 18, 2017). "FDA Approves Vagus Nerve Stimulation Device for Cluster Headache". Medscape.
  44. ^ "GammaCore Device Classification under Section 513(f)(2)(de novo)". FDA. Retrieved 6 June 2018.
  45. ^ Brauser D (January 29, 2018). "FDA Clears Vagus Nerve Stimulator for Migraine Pain". Medscape.
  46. ^ "GammaCore 510(k) Premarket Notification". FDA. Retrieved 6 June 2018.
  47. ^ "Handheld Vagus Nerve Stimulator Gets Emergency Approval for COVID-19 Use". IEEE Spectrum. 2020-07-22. Retrieved 2022-02-08.
  48. ^ Groves DA, Brown VJ (May 2005). "Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects". Neuroscience and Biobehavioral Reviews. 29 (3): 493–500. doi:10.1016/j.neubiorev.2005.01.004. PMID 15820552. S2CID 3021573.
  49. ^ de Lartigue G (October 2016). "Role of the vagus nerve in the development and treatment of diet-induced obesity". The Journal of Physiology. 594 (20): 5791–5815. doi:10.1113/JP271538. PMC 5063945. PMID 26959077.
  50. ^ Göbel CH, Tronnier VM, Münte TF (December 2017). "Brain stimulation in obesity". International Journal of Obesity. 41 (12): 1721–1727. doi:10.1038/ijo.2017.150. PMID 28663570. S2CID 20426017.
  51. ^ Herremans SC, Baeken C (September 2012). "The current perspective of neuromodulation techniques in the treatment of alcohol addiction: a systematic review" (PDF). Psychiatria Danubina. 24 (Suppl 1): S14–S20. PMID 22945180.
  52. ^ Abraham WT, Smith SA (February 2013). "Devices in the management of advanced, chronic heart failure". Nature Reviews. Cardiology. 10 (2): 98–110. doi:10.1038/nrcardio.2012.178. PMC 3753073. PMID 23229137.
  53. ^ Sabbah HN (August 2011). "Electrical vagus nerve stimulation for the treatment of chronic heart failure". Cleveland Clinic Journal of Medicine. 78 (8 suppl 1): S24–S29. doi:10.3949/ccjm.78.s1.04. PMC 3817894. PMID 21972326.
  54. ^ Fox D (4 May 2017), Can Zapping the Vagus Nerve Jump-Start Immunity? : An experimental procedure is exposing links between nervous and immune systems, Scientific American
  55. ^ Koopman FA, van Maanen MA, Vervoordeldonk MJ, Tak PP (July 2017). "Balancing the autonomic nervous system to reduce inflammation in rheumatoid arthritis". Journal of Internal Medicine. 282 (1): 64–75. doi:10.1111/joim.12626. PMID 28547815.
  56. ^ Bonaz B, Sinniger V, Pellissier S (2021). "Therapeutic Potential of Vagus Nerve Stimulation for Inflammatory Bowel Diseases". Frontiers in Neuroscience. 15: 650971. doi:10.3389/fnins.2021.650971. PMC 8019822. PMID 33828455.
  57. ^ Payne SC, Furness JB, Burns O, Sedo A, Hyakumura T, Shepherd RK, Fallon JB (2019). "Anti-inflammatory Effects of Abdominal Vagus Nerve Stimulation on Experimental Intestinal Inflammation". Frontiers in Neuroscience. 13: 418. doi:10.3389/fnins.2019.00418. PMC 6517481. PMID 31133776.
  58. ^ Hamza Z (2021-12-15). "Non-Invasive Nerve Stimulation Shows Promise for Younger IBD Patients". www.medpagetoday.com. Retrieved 2022-02-06.
  59. ^ Merrill, Charley A.; Jonsson, Michael A. G.; Minthon, Lennart; Ejnell, Hasse; C-son Silander, Hans; Blennow, Kaj; Karlsson, Mats; Nordlund, Arto; Rolstad, Sindre; Warkentin, Siegbert; Ben-Menachem, Elinor (2006-08-01). "Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year". The Journal of Clinical Psychiatry. 67 (8): 1171–1178. doi:10.4088/jcp.v67n0801. ISSN 0160-6689. PMID 16965193.
  60. ^ Broncel, A.; Bocian, R.; Kłos-Wojtczak, P.; Kulbat-Warycha, K.; Konopacki, J. (2020-02-01). "Vagal nerve stimulation as a promising tool in the improvement of cognitive disorders". Brain Research Bulletin. 155: 37–47. doi:10.1016/j.brainresbull.2019.11.011. ISSN 0361-9230. PMID 31790720. S2CID 208344249.
  61. ^ "Noninvasive Vagus Nerve Stimulation for Parkinson Disease Shows Safety, Efficacy". Neurology live. Retrieved 2022-02-07.
  62. ^ Gierthmuehlen, Mortimer; Plachta, Dennis T. T. (2016-02-01). "Effect of selective vagal nerve stimulation on blood pressure, heart rate and respiratory rate in rats under metoprolol medication". Hypertension Research. 39 (2): 79–87. doi:10.1038/hr.2015.122. ISSN 1348-4214. PMID 26581776. S2CID 21184892.
  63. ^ Annoni, Elizabeth M.; Van Helden, Dusty; Guo, Yugene; Levac, Brett; Libbus, Imad; KenKnight, Bruce H.; Osborn, John W.; Tolkacheva, Elena G. (2019). "Chronic Low-Level Vagus Nerve Stimulation Improves Long-Term Survival in Salt-Sensitive Hypertensive Rats". Frontiers in Physiology. 10: 25. doi:10.3389/fphys.2019.00025. ISSN 1664-042X. PMC 6365472. PMID 30766489.
  64. ^ Chakravarthy K, Chaudhry H, Williams K, Christo PJ (December 2015). "Review of the Uses of Vagal Nerve Stimulation in Chronic Pain Management". Current Pain and Headache Reports. 19 (12): 54. doi:10.1007/s11916-015-0528-6. PMID 26493698. S2CID 8117776.
  65. ^ Yesiltepe, Metin; Cimen, Bariscan; Sara, Yildirim (15 September 2022). "Effects of chronic vagal nerve stimulation in the treatment of β-amyloid-induced neuropsychiatric symptoms". European Journal of Pharmacology. 931: 175179. doi:10.1016/j.ejphar.2022.175179. PMID 35973478. S2CID 251558829.
  66. ^ Giraudier, Manon; Ventura-Bort, Carlos; Weymar, Mathias (2020). "Transcutaneous Vagus Nerve Stimulation (tVNS) Improves High-Confidence Recognition Memory but Not Emotional Word Processing". Frontiers in Psychology. 11: 1276. doi:10.3389/fpsyg.2020.01276. ISSN 1664-1078. PMC 7363946. PMID 32733306.
  67. ^ Kaan, Edith; De Aguiar, Ivette; Clarke, Christina; Lamb, Damon G.; Williamson, John B.; Porges, Eric C. (2021-08-01). "A transcutaneous vagus nerve stimulation study on verbal order memory". Journal of Neurolinguistics. 59: 100990. doi:10.1016/j.jneuroling.2021.100990. ISSN 0911-6044. S2CID 231705467.
  68. ^ Engineer CT, Hays SA, Kilgard MP (2017). "Vagus nerve stimulation as a potential adjuvant to behavioral therapy for autism and other neurodevelopmental disorders". Journal of Neurodevelopmental Disorders. 9: 20. doi:10.1186/s11689-017-9203-z. PMC 5496407. PMID 28690686.
  69. ^ Johnson RL, Wilson CG (2018). "A review of vagus nerve stimulation as a therapeutic intervention". Journal of Inflammation Research. 11: 203–213. doi:10.2147/JIR.S163248. PMC 5961632. PMID 29844694.
  70. ^ Puledda F, Goadsby PJ (April 2017). "An Update on Non-Pharmacological Neuromodulation for the Acute and Preventive Treatment of Migraine". Headache. 57 (4): 685–691. doi:10.1111/head.13069. PMID 28295242. S2CID 205161411.
  71. ^ Cai PY, Bodhit A, Derequito R, Ansari S, Abukhalil F, Thenkabail S, et al. (June 2014). "Vagus nerve stimulation in ischemic stroke: old wine in a new bottle". Frontiers in Neurology. 5: 107. doi:10.3389/fneur.2014.00107. PMC 4067569. PMID 25009531.
  72. ^ Shiozawa P, Silva ME, Carvalho TC, Cordeiro Q, Brunoni AR, Fregni F (July 2014). "Transcutaneous vagus and trigeminal nerve stimulation for neuropsychiatric disorders: a systematic review". Arquivos de Neuro-Psiquiatria. 72 (7): 542–547. doi:10.1590/0004-282x20140061. PMID 25054988.

Further reading[edit]